Supplementary Table S1 from EPHA2 Is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma

Authors :: Hensin Tsao
Nathanael S. Gray
Keith T. Flaherty
Jennifer A. Wargo
Raj Kumar
Dennie T. Frederick
Hwan Geun Choi
Jianming Zhang
Michael Taylor
Li Tan
Zhenyu Ji
Benchun Miao
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Supplementary Table S1. The information of the melanoma patients for EphA2 analysis.

Tools